“B-Cell Non-Hodgkin Lymphoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the B-Cell Non-Hodgkin Lymphoma Market.
The B-Cell Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report:
-
Companies across the globe are diligently working toward developing novel B-Cell Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years.
-
B-Cell Non-Hodgkin Lymphoma companies working in the treatment market are Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others, are developing therapies for the B-Cell Non-Hodgkin Lymphoma treatment
-
Emerging B-Cell Non-Hodgkin Lymphoma therapies in the different phases of clinical trials are- VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others are expected to have a significant impact on the B-Cell Non-Hodgkin Lymphoma market in the coming years.
-
In May 2024, Bristol Myers-Squibb stated that, TRANSCEND FL (NCT04245839) is a global, multicenter, open-label Phase 2 study evaluating the efficacy and safety of Breyanzi in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, including follicular lymphoma. The primary endpoint is the overall response rate, including the best overall response of complete or partial response as assessed by an Independent Review Committee. Secondary endpoints include complete response rate, duration of response, progression-free survival, and safety.
-
In March 2023, Oncternal Therapeutics, Inc. has commenced a trial named “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.” This trial aims to evaluate Zilovertamab, an ROR1 Antibody, in combination with Ibrutinib versus Ibrutinib combined with a placebo in individuals diagnosed with Relapsed or Refractory Mantle Cell Lymphoma.
-
In May 2023, Janssen Biotech, Inc., a branch of the Janssen Pharmaceutical Companies under Johnson & Johnson, has disclosed its global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG). The agreement aims to jointly develop, manufacture, and market advanced chimeric antigen receptor (CAR) T-cell therapies targeted for treating B-cell malignancies.
-
In May 2023, Genmab A/S declared that the U.S. Food and Drug Administration (FDA) has granted approval for EPKINLY™ (epcoritamab-bysp) as the inaugural and sole T-cell engaging bispecific antibody designated for treating adult patients experiencing relapsed or refractory (R/R) diffuse large B-Cell Non-Hodgkin Lymphoma (DLBCL). This includes DLBCL not otherwise specified (NOS), encompassing cases originating from indolent lymphoma, and high-grade B-Cell Non-Hodgkin Lymphoma, following two or more lines of systemic therapy.
-
In January 2023, Fate Therapeutics, Inc. disclosed their decision to reject a proposal from Janssen Biotech, Inc. (“Janssen”) regarding the continuation of their collaboration and option agreement under revised terms and conditions. Consequently, this refusal has led to the termination of the agreement, and all ongoing collaboration activities between the parties are scheduled to be concluded by the first quarter of 2023.
B-Cell Non-Hodgkin Lymphoma Overview
B-Cell Non-Hodgkin Lymphoma (B-Cell NHL) is a type of cancer that originates in the B-lymphocytes, a type of white blood cell crucial to the immune system. B-Cell NHL represents the most common form of Non-Hodgkin Lymphoma, accounting for about 85% of cases. It includes various subtypes, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma. Symptoms typically include painless swollen lymph nodes, fatigue, fever, night sweats, and unexplained weight loss. Treatments may involve chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation depending on the subtype and disease stage.
Get a Free Sample PDF Report to know more about B-Cell Non-Hodgkin Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-pipeline-insight
Emerging B-Cell Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:
-
VIP 924: Vincerx Pharma
-
UBX-303-1: Ubix Therapeutics
-
BMF-219: Biomea Fusion Inc.
-
SHR-A1912: Shanghai Hengrui Pharmaceutical
-
Ociperlimab: BeiGene
-
AUTO3: Autolus Limited
-
GNC-038: SystImmune Inc
-
Poseltinib: Hanmi Pharmaceutical
-
Abexinostat: Xynomic Pharmaceuticals
-
PF-07901801: Pfizer
-
Odronextamab: ZAI Lab
-
Zilovertamab: Oncternal Therapeutics
-
PF-07901801: Pfizer
-
LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
-
TG-1801: TG Therapeutics, Inc.
B-Cell Non-Hodgkin Lymphoma Route of Administration
B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
intravenous
-
Subcutaneous
-
Topical.
B-Cell Non-Hodgkin Lymphoma Molecule Type
B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
B-Cell Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment
-
B-Cell Non-Hodgkin Lymphoma Assessment by Product Type
-
B-Cell Non-Hodgkin Lymphoma By Stage and Product Type
-
B-Cell Non-Hodgkin Lymphoma Assessment by Route of Administration
-
B-Cell Non-Hodgkin Lymphoma By Stage and Route of Administration
-
B-Cell Non-Hodgkin Lymphoma Assessment by Molecule Type
-
B-Cell Non-Hodgkin Lymphoma by Stage and Molecule Type
DelveInsight’s B-Cell Non-Hodgkin Lymphoma Report covers around 170+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further B-Cell Non-Hodgkin Lymphoma product details are provided in the report. Download the B-Cell Non-Hodgkin Lymphoma pipeline report to learn more about the emerging B-Cell Non-Hodgkin Lymphoma therapies
Some of the key companies in the B-Cell Non-Hodgkin Lymphoma Therapeutics Market include:
Key companies developing therapies for B-Cell Non-Hodgkin Lymphoma are – Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, and others.
B-Cell Non-Hodgkin Lymphoma Pipeline Analysis:
The B-Cell Non-Hodgkin Lymphoma pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Non-Hodgkin Lymphoma Treatment.
-
B-Cell Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
B-Cell Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Non-Hodgkin Lymphoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about B-Cell Non-Hodgkin Lymphoma drugs and therapies
B-Cell Non-Hodgkin Lymphoma Pipeline Market Drivers
-
Increase in prevalence of B-Cell Non-Hodgkin Lymphoma, launch of several novel therapies for treating B cell Lymphoma are some of the important factors that are fueling the B-Cell Non-Hodgkin Lymphoma Market.
B-Cell Non-Hodgkin Lymphoma Pipeline Market Barriers
-
However, high cost of the treatment, side effects associated with the therapies and other factors are creating obstacles in the B-Cell Non-Hodgkin Lymphoma Market growth.
Scope of B-Cell Non-Hodgkin Lymphoma Pipeline Drug Insight
-
Coverage: Global
-
Key B-Cell Non-Hodgkin Lymphoma Companies: Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others
-
Key B-Cell Non-Hodgkin Lymphoma Therapies: VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others
-
B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment: B-Cell Non-Hodgkin Lymphoma current marketed and B-Cell Non-Hodgkin Lymphoma emerging therapies
-
B-Cell Non-Hodgkin Lymphoma Market Dynamics: B-Cell Non-Hodgkin Lymphoma market drivers and B-Cell Non-Hodgkin Lymphoma market barriers
Request for Sample PDF Report for B-Cell Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials
Table of Contents
1. B-Cell Non-Hodgkin Lymphoma Report Introduction
2. B-Cell Non-Hodgkin Lymphoma Executive Summary
3. B-Cell Non-Hodgkin Lymphoma Overview
4. B-Cell Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. B-Cell Non-Hodgkin Lymphoma Pipeline Therapeutics
6. B-Cell Non-Hodgkin Lymphoma Late Stage Products (Phase II/III)
7. B-Cell Non-Hodgkin Lymphoma Mid Stage Products (Phase II)
8. B-Cell Non-Hodgkin Lymphoma Early Stage Products (Phase I)
9. B-Cell Non-Hodgkin Lymphoma Preclinical Stage Products
10. B-Cell Non-Hodgkin Lymphoma Therapeutics Assessment
11. B-Cell Non-Hodgkin Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. B-Cell Non-Hodgkin Lymphoma Key Companies
14. B-Cell Non-Hodgkin Lymphoma Key Products
15. B-Cell Non-Hodgkin Lymphoma Unmet Needs
16 . B-Cell Non-Hodgkin Lymphoma Market Drivers and Barriers
17. B-Cell Non-Hodgkin Lymphoma Future Perspectives and Conclusion
18. B-Cell Non-Hodgkin Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/